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Abstract
Background: The aim of the study was identification of the predictors of left atrial tachycar-
dia and left atrial flutter (LATAFL) after radiofrequency catheter ablation of atrial fibrillation 
(CAAF). 
Methods: We followed 598 patients (71% male, 41% paroxysmal AF; median follow-up:  
36 months) after a single step-wise CAAF procedure. The time to first documented LATAFL 
lasting longer than 30 s, documented in any kind of electrocardiography (ECG), was defined 
as an end-point.
Results: A single CAAF procedure resulted in LATAF in 58 (10%) patients. Additional le-
sions were performed in 275 (46%) patients. Early LATAFL recurrence (£ 3 months since 
the index procedure) was observed in 11 (2%) patients. Late LATAFL (> 3 months) was 
noted in 47 (8%) patients. The univariate predictors of LATAFL recurrence were: type of AF  
(p = 0.003), the size of LA (p = 0.002) and the type of procedure (p = 0.0001). The identified 
single independent predictors of LATAFL recurrence were enlarged LA (p = 0.001) and mul-
tiple (≥ 2) additional lesions performed during the index procedure (p < 0.0001).
Conclusions: Higher rate of LATAFL recurrence was observed in patients with non-paroxys-
mal AF, enlarged LA and any additional lesions performed. Two independent predictors of 
LATAFL recurrence after CAAF were: the enlarged LA and multiple (≥ 2) additional lesions 
performed during the index procedure. (Cardiol J 2015; 22, 5: 557–566)
Key words: atrial fibrillation, catheter ablation, left atrial tachycardia,  
left atrial flutter
Introduction
Catheter ablation of atrial fibrillation (AF) is 
a more effective therapeutic option for patients 
with AF, as compared to antiarrhythmic drugs 
(AADs) [1]. Multiple approaches for catheter 
ablation of AF (CAAF) have been developed. The 
current techniques focus on the elimination of 
mechanisms involved in the initiation (triggers) and 
maintenance (substrate) of AF [2, 3]. While ablation 
strategies that target pulmonary veins (PVs) are 
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more extensive ablation based on linear lesions 
or complex fractionated electrograms (CFAE) are 
approached in patients with long-standing persis-
tent AF [3, 4]. Organized left atrial tachycardia 
and left atrial flutter (LATAFL) are common after 
CAAF with a reported incidence of 1.2–40% and 
the variability in the frequency of occurrence and 
the mechanism of LATAFL appears to be clearly 
dependent on the type of ablation procedure used 
and the extent of the underlying atrial disease [2]. 
Nevertheless, the predictors of LATAFL after 
CAAF are under debate [4].
The aim of the study was identification of the 
predictors of LATAFL after CAAF.
Methods
Patient characteristics
We followed 598 patients who had CAAF 
performed. The inclusion criteria, at the date of 
the procedure, were as follows: age 18–80 years, 
symptomatic and drug refractory non-valvular AF, 
AF documented in at least 2 electrocardiograms 
(ECGs) in a 3-month period preceding the abla-
tion procedure and a signed informed consent 
obtained from the patient. The exclusion criteria 
included: acute reversible causes for AF, valvular 
AF, LATAFL documented in at least 1 ECG, known 
bleeding diathesis, intolerance of heparin or oral 
anticoagulation, left atrial (LA) thrombus, preg-
nancy or breastfeeding, abuse of drugs or alcohol, 
New York Heart Association (NYHA) class IV and 
other severe co-morbidities.
Pre-ablation preparation
Medical history was obtained during a visit to 
an outpatient-clinic with a review of the medical 
records including ECGs and Holter-ECG record-
ings of AF. The risk of procedure was discussed in 
detail, and all patients gave their written informed 
consent. AADs were discontinued at least 3 days 
before the ablation. Beta-blockers were allowed 
according to the protocol.
Assessment of the left atrial size
All patients underwent transthoracic echo-
cardiography to determine LA diameter. The LA 
size was assessed by measurement of short and 
long axis in apical 4-chamber view. The normal-
ized left atrial area (NLA), previously shown to be 
a stronger predictor of outcome than both LA short 
and long axis diameters, as well as LA area was 
calculated in each case [5].
NPAF and LATAFL definition
Non-paroxysmal AF (NPAF) was defined as 
persistent, long-lasting persistent, or paroxysmal 
AF (PAF) in patients with more than 500 h in symp-
tomatic AF within 3 months prior to admission [5]. 
Left atrial tachycardia and left atrial flutter were 
defined as: (1) early LATAFL (occurring within 
the first 3 months) and (2) late LATAFL (occurring 
after the first 3 months).
Catheter ablation procedure
All procedures were performed under con-
scious sedation and analgesia. In all cases we 
used bi-plane fluoroscopy set in 60o LAO and 
30o RAO views, respectively. After local anesthesia, 
a 10- or 20-polar steerable catheter was placed in 
the coronary sinus. Two transseptal sheets were 
introduced into the LA. The ablation procedures 
were performed with a support of a 3-dimension-
al (3D) electro-anatomical mapping system (Car-
to/EnSite) or with the previously described [6] 
high-density mapping catheter, HD Mesh Map-
per™ (HDMM; Bard Electrophysiology, Lowell, 
MA, USA), placed in an antrum of the PV. A 7 F 
ThermoCool catheter (Biosense Webster) with 
a 3.5-mm irrigated tip was used for the ablation with 
radiofrequency energy settings chosen between 
15 and 35 W and a cutoff temperature of 42°C. Abla-
tion of each PV was carried out at the atrial side of 
the PV. A circumferential ablation line was performed 
around each PV, overlapping ipsilateral ablation lines.
The first step was the control of PV antrum 
isolation. In patients with sinus rhythm, the pro-
cedure was seized after confirming isolation of all 
veins, at least 30 min after last energy application. 
In patients with AF, when arrhythmia stopped 
spontaneously during PV isolation (PVI) at the 
antrum, the procedure was also aborted after con-
firming PVI. If AF continues, a stepwise approach 
including mitral isthmus line (MIL), roof line (RL), 
ablation of complex fragmented signals (CFAE) and 
endocardial lesion along coronary sinus (CSL) was 
implemented at the same procedure. When sinus 
rhythm could not be obtained during the procedure, 
cardioversion and re-mapping at sinus rhythm was 
planned at the end of procedure. The tightness of 
all linear lesions, respectively to the performed 
lesions in certain patient, and isolation of PVs and 
superior vena cava were controlled.
The acute endpoint for the procedure was 
elimination of PV antrum potentials and proving 
electrical isolation (bi-directional block) of PVs, 
superior vena cava and linear lesions, if performed.
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Post-ablation management
Intravenous flow of heparin was continued to 
achieve a partial thromboplastin time of 60–80 s. 
All patients underwent trans-thoracic echocar-
diography to exclude pericardial effusion. Oral 
anticoagulation with coumadin was started 1 day 
after CAAF, targeting an international normalized 
ratio of 2.0 to 3.0.
Follow-up
After discharge from the hospital, the patients 
were scheduled for quarterly follow-up (FU) visits. 
One year after the intervention, FU visits were per-
formed once a year. Seven-day Holter ECG record-
ings and a 12-channel ECG were obtained during each 
FU visit. Patients were asked to obtain an ECG, in 
our institution or outside, when feeling palpitations 
at times out of Holter-ECG monitoring periods.
Statistical methods
Study end-point. Time to first documented 
episode of LATAFL lasting longer than 30 s, docu-
mented in any kind of ECG was defined as an index 
parameter for a failure. Endpoint for analysis was 
the LATAFL-free survival within a FU time of 
60 months.
Statistical analysis. The effect of discrete 
variables was studied using the Kaplan-Meier 
survival analysis with log-rank test. The param-
eters were dichotomized of derived from receiving 
operator characteristics (ROC)-curve optimal 
cut-off value, i.e. at the point, where the sum 
of sensitivity and specificity reached the maxi-
mum values.  The impact of discrete variables 
on the outcome was described with positive and 
negative prediction accuracy and hazard ratio. The 
continuous data were presented as median and 
inter-quartile range, and categorical variables as 
numbers and percentages.
To avoid a potential model over-fitting, only 
the parameters revealed to be significantly as-
sociated with the outcome in univariate analysis 
were included in the multivariate Cox regression 
model performed using a step-down procedure. 
Two-tailed p values < 0.05 were considered sta-
tistically significant.
Results
Baseline and procedural characteristics
In this single-center study we included 598 
patients (median FU of 36 months) who under-
went a single CAAF procedure. The support of 3D 
electro-anatomical mapping system was used in 
191 (32%) cases. Patients’ baseline characteristics 
are summarized in Table 1.
Additional lesions were performed in 275 
(46%) patients, including: RL in 220 (37%), MIL 
in 198 (33%), CSL in 92 (15%) and CFAE elimi-
nated in 78 (13%) patients. In case of sustained 
arrhythmia, after having performed all steps of our 
protocol, the restoration of sinus rhythm with peri-
procedural direct current electricial cardioversion 
was finally executed in 169 (28%) patients.
The median of cumulative time of procedure 
and fluoroscopy was 4.5 (4.0; 5.4) h and 61 (41; 90) 
min, respectively.
LATAFL-free survival and predictors  
of outcome after a CAAF procedure
A single CAAF procedure resulted in LATAF 
in 58 (10%) patients (Fig. 1). Early (≤ 3 months 
since the index procedure) LATAFL recurrence 
was observed in 11 (2%) patients. Late (> 3 
months) LATAFL was noted in 47 (8%) patients. 
The characteristics of both groups are presented 
in Table 2.
The cut-off value of 11.5 for NLA was calcu-
lated from ROC-curve analysis. The univariate 
Table 1. Baseline characteristics (n = 598).
Parameter N (%) or median (IQR)
Male 425 (71%)
Age [years] 59 (52; 65)
History of AF [years] 4.4 (2.0; 8.2)
Paroxysmal AF 243 (41%)
Non-paroxysmal AF 355 (59%)
Body mass index 27.4 (25.2; 30.5)
Hypertension 435 (73%)




Diabetes mellitus 55 (9%)
GFR 86.9 (74.7; 101.9)
Metabolic syndrome 243 (41%)
LVEF 60 (57; 62)
LA — short axis 40 (37; 43)
LA — long axis 55 (51; 59)
LA area 21.8 (19.1; 25.2)
Normalized LA area 10.6 (9.3; 12.0)
IQR — inter-quartile range; AF — atrial fibrillation; GFR — glomeru-
lar filtration rate; LVEF — left ventricular ejection fraction; LA — left 
atrium
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predictors of LATAFL recurrence (Table 3) were: 
type of AF (p = 0.003), the size of LA (best defined 
with NLA, p = 0.002) and the type of procedure 
(p = 0.0001).
We found that the single independent pre-
dictors of LATAFL recurrence were (Table 3) 
enlarged LA, defined with NLA > 11.5 (Fig. 2A; 
p = 0.019) and multiple (≥ 2) additional 
lesions performed during the index procedure 
(Fig. 2B; p < 0.0001).
Complications
Cardiac tamponades, which occurred in 8 (1%) 
patients, were managed by pericardial puncture 
without further sequels. Pericardial effusion was 
found in 13 (2%) patients (2.17%).
Discussion
Main findings
We describe the independent predictors of 
LATAFL recurrence after CAAF: enlarged LA and 
multiple (≥ 2) additional lesions performed during 
the index procedure.
Outcome
The present study shows a 10% LATAFL re-
currence rate in 598 patients with non-valvular AF 
after a single CAAF procedure. We observed most 
LATAFL recurrence in the first 12 months after 
CAAF (Fig. 1). The analysis of previous reports 
[6–29] revealed that total LATAFL recurrence in 
5,273 patients after CAAF was 12%. Early and late 
Figure 1. Late left atrial tachycardia and left atrial flutter (LATAFL) and a 5-year outcome. Kaplan-Meier event-free 
survival curve after a single catheter ablation. We observed recurrences of any arrhythmia (atrial fibrillation/LATAFL) 
in total of 250 (41.8%) patients during the follow-up period. LATAFL was diagnosed in electrocardiogram in 58 of 
these 250 patients.
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secondary LATAFL were observed in 14% and 9% 
of patients, respectively. Higher LATAFL recur-
rence rate was found only in patients with rheu-
matic heart disease [30]. Our data are comparable 
with reported total and late LATAFL recurrence 
(10% and 8%, respectively). Lower number of early 
LATAFL recurrence in our group is the result of 
our step-wise approach, focused on elimination 
of all peri-procedural arrhythmias, which was not 
applied by any of the previous authors describing 
early LATAFL recurrence.
Types of LATAFL
Nagamoto et al. [19] described primary (pre-
procedural) and secondary (procedural-related) 
LATAFL. Both types were further defined as early 
(which appeared during a procedure) and late (af-
ter a procedure) arrhythmias. He concluded that 
Table 2. The comparison of patients with early and late left atrial tachycardia and left atrial flutter 
(LATAFL) recurrence in follow-up (FU) (n = 58).
LAT/LAFL recurrence in FU — n (%) or median (IQR) P
Early (£ 3 months) Late (> 3 months)
Baseline data
Number of patients 11 47
Male 9 (82%) 33 70% 0.710
History of AF [years] 1.38 (0.42; 2.06) 4.35 (1.9; 6.84) 0.003
Non-paroxysmal AF 11 100% 34 72% 0.055
Age [years] 62 (57; 69) 61 (56.5; 68.0) 0.548
Body mass index 25.73 (24.3; 28.7) 27.28 (25; 31) 0.475
Hypertension 10 (91%) 39 (83%)
Coronary artery disease 1 (9%) 1 (2%) 0.346
Dilated/hypertrophic cardiomyopathy 2 (18%) 2 (4%) 0.159
Diabetes mellitus 2 (18%) 1 (2%) 0.089
GFR 81.68 (74.3; 111.7) 82.54 (71.2; 94.0) 0.422
LVEF 52 (47; 57) 60 (56; 62) 0.008
LA — short axis 59 (58.0; 61.5) 56 (51.5; 61.5) 0.095
LA — long axis 43 (40.5; 45.5) 41 (38; 45) 0.232
LA area 24.94 (23.8; 27.1) 22.96 (20.5; 26.7) 0.036
Normalized LA area 12.49 (11.8; 14.1) 11.12 (10.0; 12.6) 0.017
Procedural data
PVI + at least one additional lesion 8 (73%) 36 (77%) 0.999
Roof line 7 (64%) 32 (68%) 0.999
Mitral isthmus line 7 (64%) 29 (62%) 0.999
Coronary sinus 4 (36%) 12 (26%) 0.475
CFAE 2 (18%) 11 (23%) 0.999
PVI + 1 lesion 0 7 (15%) X
PVI + ≥ 2 lesions 8 (73%) 29 (62%) 0.206
AAD in follow-up
AAD: class I 1 (9%) 8 (17%) 0.671
AAD: class II 9 (82%) 38 (81%) 0.999
AAD: class III 3 (27%) 11 (23%) 0.999
Amiodarone 2 (18%) 8 (17%) 0.999
Dronedarone 1 (9%) 2 (4%) 0.444
Sotalol 0 1 (2.1%) 0.999 
IQR — inter-quartile range; AF — atrial fibrillation; GFR — glomerular filtration rate; LVEF — left ventricular ejection fraction; LA — left atrium; 
PVI — pulmonary veins isolation; CFAE — complex fractionated electrograms; AAD — antiarrhythmic drugs
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Table 3. Predictors of outcome after a single catheter ablation of atrial fibrillation ablation procedure.
A. Continuous variables (ROC analysis) AUC 95% confidence interval P
Lower Upper
History of atrial fibrillation 0.441 0.357 0.525 0.192
Age 0.564 0.474 0.654 0.156
Body mass index 0.488 0.391 0.584 0.782
LA — long axis diameter in 4-chamber view 0.651 0.572 0.730 0.001
LA — short axis diameter in 4-chamber view 0.613 0.525 0.702 0.012
LA area 0.646 0.569 0.723 0.001
Normalized LA area 0.680 0.607 0.753 0.000
Left ventricular ejection fraction 0.555 0.473 0.637 0.165
Renal function, GFR 0.555 0.476 0.634 0.168
B. Discrete variables Hazard ratio 95% confidence interval P
Lower Upper
Non paroxysmal atrial fibrillation 2.568 1.354 4.872 0.003
Normalized LA > 11.5 2.435 1.410 4.206 0.002
Any additional lesion 4.236 2.267 7.915 0.0001
Number of lesions* ≥ 2 4.410 2.609 7.491 0.0001
C. Multivariate Cox regression model Hazard ratio 95% confidence interval p
Lower Upper
Number of lesions* ≥ 2 2.22 1.21 4.99 0.000
Enlarged LA, normalized LA > 11.5 1.88 1.11 3.19 0.019
*Any performed additional lesions are included; GFR — glomerular filtration rate; LA — left atrium
Figure 2. The size of left atrium (A), number of additional lesions (B) and a 5-year outcome. Kaplan-Meier event-free 
survival curve after a single catheter ablation; LATAFL — left atrial tachycardia and left atrial flutter; NLA — normalized 
left atrial area; PVI — pulmonary vein isolation.
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early secondary LATAFL should be ablated when 
it presented as a pre-ablation arrhythmia or a peri- 
procedurally ongoing LATAFL resulting from 
a focal or gap-related macro-reentrant mechanism 
[19]. However, the ongoing LATAFL resulting 
from non-gap-related macro-reentry (except for 
typical isthmus-dependent atrial flutter) could be 
monitored [19].
Our definition of LATAFL follows recent con-
sensus [4] and clearly demarcates peri-procedural 
(i.e. very early) from post-procedural (early, i.e. 
3-month blanking period related, and late, i.e. 
> 3 months since a procedure) LATAFL. Any peri-
procedural arrhythmia was approached according 
to our step-wise protocol. However, we cannot 
exclude that some of the observed LATAFLs, 
especially in patients after PVI only, were of the 
primary type (early or late), not identified before 
the procedure. Still, we performed a thorough 
selection of patients at inclusion, and no record 
of documented pre-procedural LATAFL was iden-
tified. Consequently, we focused on both early 
(≤ 3 months) and late (> 3 months) LATAFLs only.
Early secondary LATAFL
We observed early secondary LATAFL only 
in patients with NPAF, lower left ventricular ejec-
tion fraction and enlarged LA. All these factors 
are related to structural remodeling of LA which 
results in local substrate prone to supra-ventricular 
arrhythmias (SVA) [31]. In all these cases we per-
formed PVI and multiple additional lesions. We 
assume that such substrate modifications were 
enough for acute peri-procedural success, as we 
aimed for (following our protocol) total elimination 
of all ongoing SVA during the index procedure.
In an animal model, complete replacement 
of necrotic muscle with collagen was observed 
4 weeks after radiofrequency ablation [32]. At 10 to 
12 weeks, the replaced myocardium was less cellu-
lar and the collagen more dense. The necrotic atrial 
myocardium was replaced by a collagenous matrix 
containing small islands of surviving myocardium 
[32]. The anatomically remodeled atrium requires 
more time after ablation to reverse its vulnerability 
to triggers [33], and is more susceptible to early 
arrhythmia relapses [31]. Such a deep and wide 
injury within LA tissue needs time for local heal-
ing, i.e. the slow process of scarring which itself 
can be pro-arrhythmic. The delay in time between 
tissue injury to secondary LATAFL appearance 
could also be supported by the previous observa-
tion which showed that peri-CAAF inducibility of 
LATAFL does not predict its clinical recurrence 
in FU [18, 34]. Still, we cannot exclude the co-
existence of unknown pre-procedural or unmasked 
peri-procedural SVA. Interestingly, patients with 
early recurrence had shorter history of AF which 
further supported the idea of “healing-tissue”-re-
lated early LATAFL.
Late secondary LATAFL
Late secondary LATAFL recurrence was 
mainly observed in patients with a long history 
of AF, i.e. one of the mechanisms could be the 
continuous process of substrate remodeling within 
LA, which we hoped to slow down with CAAF, 
as curing could not be suspected in such a case. 
Subsequent explanation is the iatrogenic effect of 
any of the lesions produced, as well as gaps within 
linear lesions. Moreover, the interaction between 
the lesions and preexisting regions with abnor-
mal electrical properties cannot be excluded. As 
all above are present in LA after CAAF, the final 
mechanism of secondary LATAFL is complex in its 
nature and difficult to be simply defined.
Predictors of recurrence after CAAF
While many predictors of AF recurrence 
following CAAF have been proposed [3, 4, 35], 
predictors of LATAFL are under debate. We show 
that independent predictors of LATAFL recurrence 
after CAAF are: the enlarged LA and multiple (≥ 2) 
additional lesions performed during the index 
procedure.
Atrial enlargement, a result of atrial remod-
eling, is an important clinical predictor of AF 
maintenance [36]. The electrical remodeling in the 
atria, which results in shortening of the effective 
refractory period, is involved in the occurrence 
and maintenance of atrial fibrosis [37]. Contractile 
remodeling is evidenced by a decrease in atrial 
contractility which leads to dilation of the atria [38]. 
Structural remodeling within atria is evidenced by 
interstitial fibrosis and atrial dilatation [39]. This 
expanded the space between cardiomyocytes, like-
ly due to the loss of cells and fibrotic replacement 
and expansion of the extracellular matrix, may also 
cause conduction delays between cardiomyocytes 
themselves and allow for alternate pathways of 
conduction [39]. These changes are electrically 
apparent as ectopic foci and anisotropic conduction, 
which create non-uniform wave fronts that allow 
abnormal re-entrant arrhythmias [40]. Atrial dila-
tion increases the amount of atrial tissue that can 
accommodate reentry circuits [41]. Atrial dimen-
sions are a particularly important determinant of 
the occurrence of multiple-circuit reentry [42]. 
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Within larger atrial size more circuits can be accom-
modated and long-wavelength circuits that are too 
large for a normal-sized atrium can be supported 
[41]. Consequently, AF in the remodeled LA is not 
only trigger- but also substrate-dependent.
The iatrogenic effect of additional lesions is 
known [6–29]. Linear lesions result in linear scars 
which limit areas of LA activation. Nevertheless, 
performing linear lesions in dilated LA can be 
challenging due to the fact thatthey have to be 
longer than in not-dilated LA. The vast majority of 
arrhythmias that occur after CAAF are re-entrant 
(83%) [1–6, 8–25] and use gaps in prior ablation 
lines. Elimination of the dominant arrhythmia may 
uncover, suppressed so far, ectopic foci. Addition-
ally, electrogram-guided ablation and elimination 
of CFAE, aimed at ectopic foci, also result in many 
scattered areas of block, which in combination with 
existed regions of anisotropic conduction, promote 
substrate for re-entry. Consequently, the combina-
tion of LA enlargement and multiple lesions results 
in changed electrophysiological environment and 
development of secondary arrhythmias. Our step-
wise approach showed that avoidance of multiple 
ablation lesions cannot be avoided in many patients. 
Nevertheless, the collected data show that limit-
ing additional lesions (with step-wise approach), 
demonstration of conduction block within the lines 
and PV disconnection are likely to decrease the 
prevalence of post-CAAF LATAFL [21].
Clinical implications
Clinical implications of our results are sub-
stantial for patients planned for CAAF. Firstly, the 
outcome data should be presented. A procedure 
in patients with enlarged LA and premeditated 
for additional lesions might result in LATAFL. 
Consequently, subsequent CAAF can be needed. 
Secondly, thorough monitoring after CAAF is 
crucial. Incidence of late arrhythmia recurrence 
may be related to the extent of ECG monitoring 
and earlier recurrence may be missed in selected 
patients with no or minimal symptoms [4]. Clini-
cal evaluation should be performed on regular 
basis and any complaint of “heart palpitations” 
[43] should be addressed. Finally, attention in 
control of patient-related risk factors remains 
an integral part of management after the CAAF 
procedure [4].
Limitations of the study
Our study has a few limitations: (1) This is 
a single-center, non-randomized report. However, 
there was no selection bias for study inclusion since 
all consecutive patients undergoing radiofrequency 
catheter ablation for AF at our institution were 
included for analysis. (2) A potential variability of 
operator experiences with the stepwise ablation 
approach might further limit our results. (3) We 
did not use any protocol of LATAFL induction 
after CAAF procedure. Nevertheless, it was previ-
ously shown that arrhythmia inducibility was not 
predictive of atrial arrhythmia recurrence in FU 
[18, 34]. (4) According to the latest Consensus 
Report [4], the FU results are presented without 
consideration of recurrences during the blanking 
period. (5) The latest data [44], unknown at the 
time of selection of our study cohort, show that 
continuous monitoring with implanted devices is 
significantly superior to intermittent monitoring. 
Our FU was based on clinical evaluation and 7-day 
Holter-ECG recordings.
Conclusions
Our data show that a step-wise CAAF proce-
dure results in relatively low LATAFL recurrence 
rate in a very long-term FU. Most LATAFL recur-
rences occurred in the first 12 months if only PVI 
was performed. In patients in whom any additional 
lesions were performed, most recurrences oc-
curred in the first 30 months. A plateau in LATAFL-
free survival was noted in both groups thereafter.
Higher rate of LATAFL recurrence was ob-
served in patients with NPAF, enlarged LA and 
any additional lesions performed. We defined 
2 independent predictors of LATAFL recurrence 
after CAAF: the enlarged LA and multiple (≥ 2) addi-
tional lesions performed during the index procedure.
The presented data follow the latest indications 
for CAAF [4]. Performing CAAF at earlier stage of 
AF, in not-dilated LA, may allow limiting the need 
for additional lesions. Such an approach is likely to 
decrease the prevalence of LATAFL after CAAF.
Conflicts of interest: Dr Maciej Wójcik was support-
ed by European Heart Rhythm Association (2-year 
Clinical Electrophysiology Fellowship, 2007–2009).
References
1. Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the 
esc guidelines for the management of atrial fibrillation: An update 
of the 2010 esc guidelines for the management of atrial fibrilla-
tion. Developed with the special contribution of the european 
heart rhythm association. Eur Heart J, 2012; 33: 2719–2747.
2. Raviele A, Natale A, Calkins H et al. Venice chart international 
consensus document on atrial fibrillation ablation: 2011 update. 
J Cardiovasc Electrophysiol, 2012; 23: 890–923.
564 www.cardiologyjournal.org
Cardiology Journal 2015, Vol. 22, No. 5
3. Wójcik M, Berkowitsch A, Greiss H et al. Repeated catheter abla-
tion of atrial fibrillation. Circ J, 2013; 77: 2271–2279.
4. Calkins H, Kuck KH, Cappato R et al. 2012 hrs/ehra/ecas expert 
consensus statement on catheter and surgical ablation of atrial 
fibrillation: Recommendations for patient selection, procedural 
techniques, patient management and follow-up, definitions, end-
points, and research trial design. Europace, 2012; 14: 528–606.
5. Berkowitsch A, Neumann T, Kuniss M et al. Therapy with renin-
angiotensin system blockers after pulmonary vein isolation in 
patients with atrial fibrillation: Who is a responder? Pacing Clin 
Electrophysiol, 2010; 33: 1101–1111.
6. Neumann T, Kuniss M, Erkapic D et al. Acute and long-term 
results of pvi at antrum using a novel high-density mapping 
catheter without help of 3d electro-anatomic mapping in patients 
with paroxysmal and chronic atrial fibrillation. J Interv Card 
Electrophysiol, 2010; 27: 101–108.
7. Chugh A, Oral H, Lemola K et al. Prevalence, mechanisms, and 
clinical significance of macroreentrant atrial tachycardia dur-
ing and following left atrial ablation for atrial fibrillation. Heart 
Rhythm, 2005; 2: 464–471.
8. Daoud EG, Weiss R, Augostini R et al. Proarrhythmia of circum-
ferential left atrial lesions for management of atrial fibrillation. 
J Cardiovasc Electrophysiol, 2006; 17: 157–165.
9. Ouyang F, Antz M, Ernst S et al. Recovered pulmonary vein 
conduction as a dominant factor for recurrent atrial tachyar-
rhythmias after complete circular isolation of the pulmonary 
veins: Lessons from double lasso technique. Circulation, 2005; 
111: 127–135.
10. Pappone C, Manguso F, Vicedomini G et al. Prevention of iatro-
genic atrial tachycardia after ablation of atrial fibrillation: A pro-
spective randomized study comparing circumferential pulmonary 
vein ablation with a modified approach. Circulation, 2004; 110: 
3036–3042.
11. Shah D, Sunthorn H, Burri H et al. Narrow, slow-conducting 
isthmus dependent left atrial reentry developing after ablation 
for atrial fibrillation: ECG characterization and elimination by fo-
cal RF ablation. J Cardiovasc Electrophysiol, 2006; 17: 508–515.
12. Villacastin J, Perez-Castellano N, Moreno J, Gonzalez R. Left 
atrial flutter after radiofrequency catheter ablation of focal atrial 
fibrillation. J Cardiovasc Electrophysiol, 2003; 14: 417–421.
13. Deisenhofer I, Estner H, Zrenner B et al. Left atrial tachycardia 
after circumferential pulmonary vein ablation for atrial fibrilla-
tion: Incidence, electrophysiological characteristics, and results 
of radiofrequency ablation. Europace, 2006; 8: 573–582.
14. Ernst S, Ouyang F, Lober F, Antz M, Kuck KH. Catheter-induced 
linear lesions in the left atrium in patients with atrial fibrilla-
tion: An electroanatomic study. J Am Coll Cardiol, 2003; 42: 
1271–1282.
15. Gerstenfeld EP, Callans DJ, Dixit S et al. Mechanisms of orga-
nized left atrial tachycardias occurring after pulmonary vein 
isolation. Circulation, 2004; 110: 1351–1357.
16. Hocini M, Sanders P, Jais P et al. Prevalence of pulmonary vein 
disconnection after anatomical ablation for atrial fibrillation: Con-
sequences of wide atrial encircling of the pulmonary veins. Eur 
Heart J, 2005; 26: 696–704.
17. Karch MR, Zrenner B, Deisenhofer I et al. Freedom from atrial 
tachyarrhythmias after catheter ablation of atrial fibrillation: 
A randomized comparison between 2 current ablation strategies. 
Circulation, 2005; 111: 2875–2880.
18. Leong-Sit P, Robinson M, Zado ES et al. Inducibility of atrial 
fibrillation and flutter following pulmonary vein ablation. J Car-
diovasc Electrophysiol, 2013; 24: 617–623.
19. Nagamoto Y, Tsuchiya T, Miyamoto K, Yamaguchi T, Takahashi 
N. Atrial tachycardia during ongoing atrial fibrillation ablation. 
Ensite array analysis. Circ J, 2011; 75: 1080–1089.
20. Sawhney N, Anousheh R, Chen W, Feld GK. Circumferential pul-
monary vein ablation with additional linear ablation results in an 
increased incidence of left atrial flutter compared with segmental 
pulmonary vein isolation as an initial approach to ablation of par-
oxysmal atrial fibrillation. Circulation Arrhythmia Electrophysiol, 
2010; 3: 243–248.
21. Chae S, Oral H, Good E et al. Atrial tachycardia after circumfer-
ential pulmonary vein ablation of atrial fibrillation: Mechanistic 
insights, results of catheter ablation, and risk factors for recur-
rence. J Am Coll Cardiol, 2007; 50: 1781–1787.
22. Chang SL, Tsao HM, Lin YJ et al. Differentiating macroreentrant 
from focal atrial tachycardias occurred after circumferential pul-
monary vein isolation. J Cardiovasc Electrophysiol, 2011; 22: 
748–755.
23. Cummings JE, Schweikert R, Saliba W et al. Left atrial flutter 
following pulmonary vein antrum isolation with radiofrequency 
energy: Linear lesions or repeat isolation. J Cardiovasc Electro-
physiol, 2005; 16: 293–297.
24. Jais P, Hocini M, Hsu LF et al. Technique and results of linear 
ablation at the mitral isthmus. Circulation, 2004; 110: 2996–3002.
25. Kanagaratnam L, Tomassoni G, Schweikert R et al. Empirical 
pulmonary vein isolation in patients with chronic atrial fibrilla-
tion using a three-dimensional nonfluoroscopic mapping sys-
tem: Long-term follow-up. Pacing Clin. Electrophysiol, 2001; 24: 
1774–1779.
26. Oral H, Scharf C, Chugh A et al. Catheter ablation for paroxysmal 
atrial fibrillation: Segmental pulmonary vein ostial ablation ver-
sus left atrial ablation. Circulation, 2003; 108: 2355–2360.
27. Oral H, Chugh A, Lemola K et al. Noninducibility of atrial fibril-
lation as an end point of left atrial circumferential ablation for 
paroxysmal atrial fibrillation: A randomized study. Circulation, 
2004; 110: 2797–2801.
28. Rostock T, Drewitz I, Steven D et al. Characterization, mapping, 
and catheter ablation of recurrent atrial tachycardias after step-
wise ablation of long-lasting persistent atrial fibrillation. Circula-
tion Arrhythmia Electrophysiology, 2010; 3: 160–169.
29. Sotomi Y, Inoue K, Ito N et al. Cause of very late recurrence of 
atrial fibrillation or flutter after catheter ablation for atrial fibril-
lation. Am J Cardiol, 2013; 111: 552–556.
30. Wang XH, Huang CX, Liu X et al. Ablation of atrial tachycardia 
occurring after catheter ablation of atrial fibrillation in patients 
with corrected rheumatic valve disease. J Interv Card Electro-
physiol, 2012; 35: 45–56.
31. Bertaglia E, Stabile G, Senatore G et al. Predictive value of 
early atrial tachyarrhythmias recurrence after circumferential 
anatomical pulmonary vein ablation. Pacing Clin Electrophysiol, 
2005; 28: 366–371.
32. Taylor GW, Kay GN, Zheng X, Bishop S, Ideker RE. Pathological 
effects of extensive radiofrequency energy applications in the 
pulmonary veins in dogs. Circulation, 2000; 101: 1736–1742.
33. Allessie MA. Atrial electrophysiologic remodeling: Another vi-
cious circle? J Cardiovasc Electrophysiol, 1998; 9: 1378–1393.
34. Kurotobi T, Shimada Y, Kino N et al. Inducible atrial tachycardias 
with multiple circuits in a stepwise approach are associated with 
increased episodes of atrial tachycardias after catheter ablation. 
J Electrocardiol, 2012; 45: 102–108.
35. Wojcik M, Erkapic D, Berkowitsch A et al. Ipsilateral circumfer-
ential radiofrequency ablation of atrial fibrillation with irrigated 
tip catheter. Circ J, 2013; 77: 2280–2287.
www.cardiologyjournal.org 565
Maciej Wójcik et al., Predictors of early and late LATAFL after CAAF
36. Henry WL, Morganroth J, Pearlman AS et al. Relation between 
echocardiographically determined left atrial size and atrial fibril-
lation. Circulation, 1976; 53: 273–279.
37. Van Wagoner DR. Electrophysiological remodeling in human atri-
al fibrillation. Pacing Clin Electrophysiol, 2003; 26: 1572–1575.
38. Schotten U, de Haan S, Neuberger HR et al. Loss of atrial con-
tractility is primary cause of atrial dilatation during first days of 
atrial fibrillation. Am J Physiol Heart Circ Physiol, 2004; 287: 
H2324–2331.
39. Pellman J, Lyon RC, Sheikh F. Extracellular matrix remodeling in 
atrial fibrosis: Mechanisms and implications in atrial fibrillation. 
J Mol Cell Cardiol, 2010; 48: 461–467.
40. Eckstein J, Verheule S, de Groot NM, Allessie M, Schotten U. 
Mechanisms of perpetuation of atrial fibrillation in chronically 
dilated atria. Prog Biophys Mol Biol, 2008; 97: 435–451.
41. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fi-
brillation: Mechanisms and implications. Circulation Arrhythmia 
Electrophysiol, 2008; 1: 62–73.
42. Zou R, Kneller J, Leon LJ, Nattel S. Substrate size as a determi-
nant of fibrillatory activity maintenance in a mathematical model 
of canine atrium. Am J Physiol Heart Circ Physiol, 2005; 289: 
H1002–H1012.
43. Neumann T, Erdogan A, Dill T et al. Asymptomatic recurrences 
of atrial fibrillation after pulmonary vein isolation. Europace, 
2006; 8: 495–498.
44. Charitos EI, Stierle U, Ziegler PD et al. A comprehensive evalu-
ation of rhythm monitoring strategies for the detection of atrial 
fibrillation recurrence: Insights from 647 continuously monitored 
patients and implications for monitoring after therapeutic inter-
ventions. Circulation, 2012; 126: 806–814.
566 www.cardiologyjournal.org
Cardiology Journal 2015, Vol. 22, No. 5
